Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal

Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet